Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis

G M Murray; N Griffith; P Sinnappurajar; D A Al Julandani; S L N Clarke; D P Hawley; Jessy Choi; C M Guly; Athimalaipet V Ramanan

doi:10.1080/09273948.2023.2172591

Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis

G M Murray, N Griffith, P Sinnappurajar, D A Al Julandani, S L N Clarke, D P Hawley, Jessy Choi, C M Guly, Athimalaipet V Ramanan^*

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

6 Citations (Scopus)

Abstract

BACKGROUND: Adalimumab has demonstrated efficacy in non-infectious uveitis. With the introduction of biosimilar agents such as Amgevita, we aimed to quantify efficacy and tolerability compared to Humira in a multi-centre UK cohort.

METHODS: Patients identified from tertiary uveitis clinics in 3 centres, after institution-mandated switching was implemented.

RESULTS: Data collected for 102 patients, aged 2-75 years, with 185 active eyes. Following switch, rates of uveitis flare were not significantly different (13 events before, 21 after, p = .132). Rates of elevated intraocular pressure were decreased (32 before, 25 afterwards, p = .006) and dosing of oral and intra-ocular steroids was stable. Twenty-four patients (24%) requested to return to Humira, commonly due to pain from injection or technical difficulty with the device.

CONCLUSION: Amgevita is safe and effective for inflammatory uveitis with non-inferiority to Humira. Significant numbers of patients requested to switch back due to side effects including injection site reactions.

Original language	English
Pages (from-to)	442-446
Number of pages	5
Journal	Ocular Immunology and Inflammation
Volume	32
Issue number	4
Early online date	21 Feb 2024
DOIs	https://doi.org/10.1080/09273948.2023.2172591
Publication status	Published - 20 Apr 2024

Bibliographical note

Publisher Copyright:
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

Keywords

Humans
Adalimumab/therapeutic use
Uveitis/drug therapy
Middle Aged
Female
Male
Adult
Biosimilar Pharmaceuticals/therapeutic use
Adolescent
Aged
Child
Child, Preschool
Young Adult
Treatment Outcome
Retrospective Studies
Anti-Inflammatory Agents/therapeutic use
Drug Substitution

Access to Document

10.1080/09273948.2023.2172591Licence: CC BY

Handle.net

Persistent link

Cite this

@article{c489edfc7d3e4b98b9c1ad43ff26479d,

title = "Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis",

abstract = "BACKGROUND: Adalimumab has demonstrated efficacy in non-infectious uveitis. With the introduction of biosimilar agents such as Amgevita, we aimed to quantify efficacy and tolerability compared to Humira in a multi-centre UK cohort.METHODS: Patients identified from tertiary uveitis clinics in 3 centres, after institution-mandated switching was implemented.RESULTS: Data collected for 102 patients, aged 2-75 years, with 185 active eyes. Following switch, rates of uveitis flare were not significantly different (13 events before, 21 after, p = .132). Rates of elevated intraocular pressure were decreased (32 before, 25 afterwards, p = .006) and dosing of oral and intra-ocular steroids was stable. Twenty-four patients (24%) requested to return to Humira, commonly due to pain from injection or technical difficulty with the device.CONCLUSION: Amgevita is safe and effective for inflammatory uveitis with non-inferiority to Humira. Significant numbers of patients requested to switch back due to side effects including injection site reactions.",

keywords = "Humans, Adalimumab/therapeutic use, Uveitis/drug therapy, Middle Aged, Female, Male, Adult, Biosimilar Pharmaceuticals/therapeutic use, Adolescent, Aged, Child, Child, Preschool, Young Adult, Treatment Outcome, Retrospective Studies, Anti-Inflammatory Agents/therapeutic use, Drug Substitution",

author = "Murray, {G M} and N Griffith and P Sinnappurajar and {Al Julandani}, {D A} and Clarke, {S L N} and Hawley, {D P} and Jessy Choi and Guly, {C M} and Ramanan, {Athimalaipet V}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2024",

month = apr,

day = "20",

doi = "10.1080/09273948.2023.2172591",

language = "English",

volume = "32",

pages = "442--446",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Taylor & Francis Group",

number = "4",

}

TY - JOUR

T1 - Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis

AU - Murray, G M

AU - Griffith, N

AU - Sinnappurajar, P

AU - Al Julandani, D A

AU - Clarke, S L N

AU - Hawley, D P

AU - Choi, Jessy

AU - Guly, C M

AU - Ramanan, Athimalaipet V

PY - 2024/4/20

Y1 - 2024/4/20

N2 - BACKGROUND: Adalimumab has demonstrated efficacy in non-infectious uveitis. With the introduction of biosimilar agents such as Amgevita, we aimed to quantify efficacy and tolerability compared to Humira in a multi-centre UK cohort.METHODS: Patients identified from tertiary uveitis clinics in 3 centres, after institution-mandated switching was implemented.RESULTS: Data collected for 102 patients, aged 2-75 years, with 185 active eyes. Following switch, rates of uveitis flare were not significantly different (13 events before, 21 after, p = .132). Rates of elevated intraocular pressure were decreased (32 before, 25 afterwards, p = .006) and dosing of oral and intra-ocular steroids was stable. Twenty-four patients (24%) requested to return to Humira, commonly due to pain from injection or technical difficulty with the device.CONCLUSION: Amgevita is safe and effective for inflammatory uveitis with non-inferiority to Humira. Significant numbers of patients requested to switch back due to side effects including injection site reactions.

AB - BACKGROUND: Adalimumab has demonstrated efficacy in non-infectious uveitis. With the introduction of biosimilar agents such as Amgevita, we aimed to quantify efficacy and tolerability compared to Humira in a multi-centre UK cohort.METHODS: Patients identified from tertiary uveitis clinics in 3 centres, after institution-mandated switching was implemented.RESULTS: Data collected for 102 patients, aged 2-75 years, with 185 active eyes. Following switch, rates of uveitis flare were not significantly different (13 events before, 21 after, p = .132). Rates of elevated intraocular pressure were decreased (32 before, 25 afterwards, p = .006) and dosing of oral and intra-ocular steroids was stable. Twenty-four patients (24%) requested to return to Humira, commonly due to pain from injection or technical difficulty with the device.CONCLUSION: Amgevita is safe and effective for inflammatory uveitis with non-inferiority to Humira. Significant numbers of patients requested to switch back due to side effects including injection site reactions.

KW - Humans

KW - Adalimumab/therapeutic use

KW - Uveitis/drug therapy

KW - Middle Aged

KW - Female

KW - Male

KW - Adult

KW - Biosimilar Pharmaceuticals/therapeutic use

KW - Adolescent

KW - Aged

KW - Child

KW - Child, Preschool

KW - Young Adult

KW - Treatment Outcome

KW - Retrospective Studies

KW - Anti-Inflammatory Agents/therapeutic use

KW - Drug Substitution

U2 - 10.1080/09273948.2023.2172591

DO - 10.1080/09273948.2023.2172591

M3 - Article (Academic Journal)

C2 - 36803373

SN - 0927-3948

VL - 32

SP - 442

EP - 446

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 4

ER -

Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis

Abstract

Bibliographical note

Keywords

Access to Document

Handle.net

Fingerprint

Cite this